

1653
IPW

CERTIFICATE OF MAILING
37 C.F.R. § 1.8

I hereby certify that this correspondence is being deposited with the U.S. Postal Service with sufficient postage as First Class Mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the date below:

January 28, 2005
Date


Shelley P.M. Fussey

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:
Mark Leslie Smythe and
Wim Denis Frans Meutermans

Serial No.: 09/787,840

Filed: July 06, 2001

For: Auxiliary for Amide Bond Formation

Group Art Unit: 1653

Examiner: Kam

Atty. Dkt. No.: 4050.001100

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

In compliance with the duty of disclosure under 37 C.F.R. § 1.56, it is respectfully requested that this Supplemental Information Disclosure Statement be entered and the documents listed on attached Form PTO-1449 be considered by the Examiner and made of record in the present case. Copies of the listed documents required by 37 C.F.R. § 1.98(a)(2) are enclosed for the convenience of the Examiner.

In accordance with 37 C.F.R. §§ 1.97(g),(h), this Supplemental Information Disclosure Statement is not to be construed as a representation that a search has been made, and is not to be construed to be an admission that the information cited is, or is considered to be, material to patentability as defined in 37 C.F.R. § 1.56(b).

The present Supplemental Information Disclosure Statement is being filed prior to the receipt of a first Official Action reflecting an examination on the merits, and hence is timely filed in accordance with 37 C.F.R. § 1.97(b). Therefore, no fees should be required.

The items of information contained in this Supplemental Information Disclosure Statement were cited in the European counterpart to U.S. Application Serial No. 09/806,036, which is referred to in the present specification. The items of information from the European counterpart have also been disclosed in U.S. Application Serial No. 09/806,036, which is being handled by the same examiner. It is therefore believed that the examiner is already aware of the presently disclosed information.

No fees are believed to be due in connection with the filing of this Supplemental Information Disclosure Statement. However, should an Official Action recently have been mailed and should a fee be required to enter and consider this Supplemental Information Disclosure Statement under 37 C.F.R. § 1.97(c), or should any other fees be deemed necessary, such fees should be deducted from Williams, Morgan & Amerson Deposit Account No. 50-0786/4050.001100.


Respectfully submitted
Williams, Morgan & Amerson, P.C.
Customer No. 23820



Shelley P.M. Fussey, Ph.D.
Reg. No. 39,458
Agent for Applicants

10333 Richmond, Suite 1100
Houston, Texas, 77042
(713) 934-4079

Date: January 28, 2005



Form PTO-1449 (modified)

List of Patents and Publications for Applicant's

INFORMATION DISCLOSURE STATEMENT

(Use several sheets if necessary)

Atty. Docket No.
4050.001100Serial No.
09/787,840Applicant
Smythe and MeutermansFiling Date:
March 22, 2001Group:
1653U.S. Patent Documents
*See Page*Foreign Patent Documents
*See Page*Other Art
See Page 1

U.S. Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Name	Class	Sub Class	Filing Date of App.

Foreign Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Country	Class	Sub Class	Translation Yes/No

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
	C20	Beusen <i>et al.</i> , "Conformational Mimicry: Synthesis and Solution Conformation of a Cyclic Somatostatin Hexapeptide Containing a Tetrazole cis Amide Bond Surrogate," <i>Biopolymers</i> , 36(2):181-260, 1995.
	C21	Botti <i>et al.</i> , "Cyclic Peptides from Linear Unprotected Peptide Precursors Through Thiazolidine Formation," <i>J. Am. Chem. Soc.</i> , 118(42):10018-10024, 1996.
	C22	Elseviers <i>et al.</i> , "Evidence for the Bioactive Conformation in a Cyclic Hexapeptide Analogue of Somatostatin Containing a cis Peptide Bond Mimic," <i>Biochem. Biophys. Res. Comm.</i> , 154(2):515-521, 1988.
	C23	Ruckle <i>et al.</i> , "Pseudo-Prolines in Cyclic Peptides: Conformational Stabilisation of cyclo[Pro-Thr($\psi^{Me, Me}$ pro)-Pro]," <i>Tetrahedron</i> , 55(37):11281-11288, 1999.
	C24	Sakurada <i>et al.</i> , "Antinociceptive Mechanisms of [D-Arg ²]-Dermorphin Tripeptide Analogs," <i>J. Pharmacol. Exp. Therap.</i> , 263(2):793-799, 1992.
	C25	Salvadori <i>et al.</i> , "Synthesis and Pharmacological Activity of Dermorphin and Its N-Terminal Sequences," <i>Int. J. Peptide Protein Res.</i> , 19(5):536-542, 1982.
	C26	Zhang and Tam, "Lactone and Lactam Library Synthesis by Silver Ion-Assisted Orthogonal Cyclization of Unprotected Peptides," <i>J. Am. Chem. Soc.</i> , 121:3311-3320, 1999.
	C27	Zhang and Tam, "Synthesis and Application of Unprotected Cyclic Peptides as Building Blocks for Peptide Dendrimers," <i>J. Am. Chem. Soc.</i> , 119:2363-2370, 1997.
	C28	Partial European Search Report for European Counterpart Application No. 99948610.3, mailed July 16, 2004.
	C29	Partial Supplementary European Search Report for European Counterpart Application No. 99948610.3, mailed September 12, 2002.

EXAMINER:

DATE CONSIDERED:

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.